Lake Street analyst Ben Klieve lowered the firm’s price target on Bioceres (BIOX) to $8 from $13 and keeps a Buy rating on the shares. Preliminary revenue and earnings results were “nowhere near even the low end of consensus” notes the analyst, who looks for material updates on next week’s earnings call for how the company is addressing the underlying challenges that are both internal and external.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue